CoChat

Fenofibrate and the kidney: an overview

Kostapanos, Michael S., Florentin, Matilda, Elisaf, Moses S. · 2013 · European Journal of Clinical Investigation
Cited by 65

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Background: Fenofibrate has been used for the management of atherogenic dyslipidaemia for many years. Reports of fenofibrate‐associated increases in serum creatinine (SC r) levels raised concerns regarding deleterious effects on renal function. Design: In this narrative review, we discuss available literature on the effect of fenofibrate on the kidney. Results: Most clinical studies showed a rapid (within weeks) raising effect of fenofibrate on SC r levels. This was often accompanied by declined estimated glomerular filtration rate. Risk predictors of this adverse effect might include increased age, impaired renal function and high‐dose treatment. Also, the concomitant use of medications affecting renal hemodynamics (e.g. angiotensin‐converting enzyme‐inhibitors (ACEi) and angiotensin receptor blockers) may predispose to fenofibrate‐associated increased SC r levels. Interestingly, SC r increases by fenofibrate were transient and reversible even without treatment discontinuation. Furthermore, fenofibrate was associated with a slower progression of renal function impairment and albuminuria in a long‐term basis. Also, fenofibrate might be protective against pathological changes in diabetic nephropathy and hypertensive glomerulosclerosis. In this context, it is uncertain whether fenofibrate‐associated increase in SC r levels mirrors true renal function deterioration. Several theories have been expressed. The most dominant one involved the inhibition of renal vasodilatory prostaglandins reducing renal plasma flow and glomerular pressure. Increased creatinine secretion or reduced creatinine clearance by fenofibrate was also suggested. These hypotheses should be settled by further studies. Conclusions: Fenofibrate may not be a nephrotoxic drug. However, a close monitoring of SC r levels is relevant especially in high‐risk patients. Increases in SC r levels ≥30% can impose treatment discontinuation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/eci.12068

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 65

Metadata

Authors
Kostapanos, M. S., Florentin, M., & Elisaf, M. S.
Venue
European Journal of Clinical Investigation
Publisher
Wiley
Published
2013-03-11
Volume
43
Issue
5
Pages
522-531
ISSN
  • 0014-2972 (ISSN-L)
  • 1365-2362
OpenAlex
W2092666385
Cited by
65
References
23
FWCI
4.42
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.